4 vials — 10% off · 10 vials — 20% off | Volume discounts applied automatically at checkout
peptides-pro — research peptides

This drug delayed rheumatoid arthritis for years after treatment ended

A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk. Researchers found that just one year of treatment with the immune-targeting drug abatacept delayed the onset of rheumatoid arthritis by up to four years, with ben...

A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk. Researchers found that just one year of treatment with the immune-targeting drug abatacept delayed the onset of rheumatoid arthritis by up to four years, with benefits lasting long after treatment ended.
WhatsApp